Other studies have examined various DC vaccine approaches, including OK432-pulsed DCs administered intratumorally with LAK cells stimulated with an anti-CD3 monoclonal antibody (CD3-LAKs) and gemcitabine [27], α-Gal epitope-expressing tumor cell-pulsed DCs [28], DCs pulsed with MHC-I/II-restricted WT1 epitopes [29], and an hTERT, CEA, and survivin peptide-pulsed DC vaccine with a toll-like receptor (TLR)-3 adjuvant [30]. This evidence concerns the gene CEACAM7 and neoplasm.